Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Operating activities
Net loss	$ (8,842,852)	$ (3,406,512)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	9,799	5,103
Stock-based compensation	1,471,780	$ 366,868
Change in fair value of warrants	(19,807)
Issuance of restricted common stock for services	1,958,450
Increase (decrease) in operating assets and liabilities:
Grants receivable	(52,272)	$ (62,492)
Other receivables	(106,010)
Prepaid expenses and other	213,426	$ 11,022
Accounts payable	(331,501)	790,064
Accrued clinical operations and site costs	(134,569)	(297,670)
Accrued compensation	220,857	(21,224)
Other accrued expenses	307,090	100,746
Net cash used in operating activities	(5,305,609)	(2,514,095)
Investing activities
Purchases of property and equipment	(35,154)	(13,502)
Net cash used in investing activities	$ (35,154)	(13,502)
Financing activities
Issuances of preferred stock, net of issuance costs		2,973,655
Issuances of common stock, net of issuance costs	$ 11,046,348	$ 325,400
Proceeds from exercise of stock options	$ 800
Proceeds from exercise of Series B warrant		$ 1,942
Net cash provided by financing activities	$ 11,047,148	3,300,997
Net change in cash and cash equivalents	5,706,385	773,400
Cash and cash equivalents at beginning of year	1,477,143	354,254
Cash and cash equivalents at end of year	7,183,528	$ 1,127,654
Supplemental disclosure:
Cash paid during the period for income taxes	1,600
Supplemental disclosures of non-cash investing and financing information:
Deemed dividend on beneficial conversion feature for preferred stock	17,852,921	$ 2,214,911
Accretion of redemption value for Series A-1, B and C-1 convertible preferred stock	$ 93,234	93,764
Issuance of common stock for accounts payable		$ 240,000
Conversion of Series A-1 redeemable preferred stock into common stock	$ 162,968
Conversion of Series C preferred stock to common stock	966
Conversion of Series B preferred stock to common stock	160,380
Conversion of Series D preferred stock to common stock	$ 400
Subscription receivable for common stock		$ 75,000
Exchange of Series A-1 preferred stock and warrants into common stock and Series D convertible preferred stock	$ 13,111,280
Exchange of Series B preferred stock and warrants into common stock and Series D convertible preferred stock	10,451,783
Warrants exercised to purchase common stock on a cashless basis	$ 12,198